Specialty code 183500000X · Sacramento, CA
NPI
1417326364
Since 2015
Specialty
Specialty code 183500000X
Code 183500000X
Group practices
0
Medicare group memberships
Hospitals
0
Hospital affiliations
2345 Fair Oaks Blvd
Sacramento, CA, 95825
Phone (916) 480-6526
Medicare paid
-
No Medicare services published
Medicare patients
-
Drug cost, 2024
$293K
2,235 prescriptions
Company payments
-
None reported
Medicare prescription drug claims, 2024
In 2024, the drug Garrett Foo prescribed most often to Medicare patients was Atorvastatin Calcium, with 289 prescriptions and refills. In total Garrett Foo wrote 2,235 Medicare prescriptions that cost $293K.
| Drug |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-11-23.
| Claims |
|---|
| 30-day fills |
|---|
| Patients |
|---|
| Cost |
|---|
| Atorvastatin Calcium Generic | 289 | 945 | 111 | $3,522 |
| Metformin Hcl Er Metformin Hcl | 251 | 832 | 95 | $2,679 |
| Metformin Hcl Generic | 204 | 673 | 79 | $2,694 |
| Glipizide Generic | 195 | 621 | 76 | $2,739 |
| Glipizide Er Glipizide | 105 | 334 | 37 | $3,340 |
| Insulin Glargine-Yfgn Generic | 102 | 289 | 47 | $16K |
| Jardiance Empagliflozin | 102 | 332 | 45 | $60K |
| Humulin N Insulin Nph Human Isophane | 93 | 278 | 41 | $17K |
| Humulin R Insulin Regular, Human | 89 | 260 | 33 | $16K |
| Ozempic Semaglutide | 78 | 83 | 19 | $60K |
| Veo Insulin Syringe Syringe-Needle,insulin,0.5 Ml | 75 | 217 | 33 | $1,959 |
| Losartan Potassium Generic | 52 | 173 | 22 | $670 |
| Simvastatin Generic | 52 | 173 | 19 | $617 |
| Ultra-Fine Nano Pen Needle Pen Needle, Diabetic | 49 | 138 | 21 | $1,551 |
| Amlodipine Besylate Generic | 49 | 163 | 17 | $662 |
Brand drugs: 649 claims; generic drugs: 1,432 claims.
Money and other things of value reported by the companies
No payments from drug or medical device companies to Garrett Foo were reported in the years we have.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.